# Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

> **NCT03047083** · — · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 1027 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **OTHER:** Treatment patterns among AML patients
- **OTHER:** AML-related healthcare resources

## Key facts

- **NCT ID:** NCT03047083
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-02
- **Primary completion:** 2016-03-18
- **Final completion:** 2016-03-18
- **Target enrollment:** 1027 (ACTUAL)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03047083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03047083, "Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03047083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*